A Double-Blind Placebo-Controlled Preliminary Study of the Efficacy Safety and Tolerability of ST101 in the Treatment of Alzheimer
M
Martin Farlow, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
No Description Available
Description
No Description Available
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Alzheimer
-
Age: Between 50 Years - 100 Years
-
Gender: All
Updated on
23 Apr 2024.
Study ID: 1010002688 (0902-04)
